Ironwood Pharmaceuticals, Inc. - (IRWD) News
Filter IRWD News Items
IRWD News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
IRWD News Highlights
- IRWD's 30 day story count now stands at 8.
- Over the past 26 days, the trend for IRWD's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- TOP, BEAT and ID are the most mentioned tickers in articles about IRWD.
Latest IRWD News From Around the Web
Below are the latest news stories about IRONWOOD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IRWD as an investment opportunity.
Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare ConferenceBOSTON, November 21, 2023--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 9:00 a.m. ET at the Lotte New York Palace. |
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call TranscriptIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2023 Earnings Call Transcript November 9, 2023 Ironwood Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.09 EPS, expectations were $0.17. Operator: Thank you for standing by. My name is Aaron, and I will be your conference operator for today. At this time, I would like to welcome everyone […] |
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume RisesIronwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line. |
Q3 2023 Ironwood Pharmaceuticals Inc Earnings CallQ3 2023 Ironwood Pharmaceuticals Inc Earnings Call |
Ironwood Pharmaceuticals Inc (IRWD) Reports Growth in LINZESS Sales and Maintains Full Year GuidanceThird Quarter 2023 Financial Results and Business Highlights |
Top 11 Extreme Value Stocks To BuyIn this article, we discuss the top 11 extreme value stocks to buy. To skip the detailed analysis and performance history of value stocks, go directly to the Top 5 Extreme Value Stocks To Buy. Value investing is an investment strategy that aims to find stocks that the market underestimates and are trading below their […] |
Ironwood Pharmaceuticals Reports Third Quarter 2023 ResultsBOSTON, November 09, 2023--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2023 results and recent business performance. |
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update CallBOSTON, October 26, 2023--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 9, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s website at www.ir |
Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific MeetingBOSTON, October 23, 2023--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented new data from four scientific abstracts during the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting and Postgraduate Course. These data provide further insight into the impact of linaclotide on symptoms of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), as well as the burden of these disorders on patients |
Decoding Ownership and Performance: Ironwood Pharmaceuticals Inc(IRWD)Detailed Analysis of Institutional and Insider Ownership Trends of Ironwood Pharmaceuticals Inc |